<DOC>
	<DOCNO>NCT00629811</DOCNO>
	<brief_summary>This single-centre , double-blind , Placebo-controlled , randomised trial . Trial subject receive four 1cm incisional wound inner aspect upper arm ( eight total ) , give four pair anatomically match wound sit per subject . Each subject act control . One site anatomical wound pair randomly treat intradermally administer avotermin ( Juvista:100μL per linear cm wound site pre-operatively 100μL per linear cm wound margin post-wounding Day 0 Day 1 , 400μL per wound site ) second site pair control , treat Placebo ( 100μL per linear cm wound site pre-operatively 100μL per linear cm wound margin post-wounding Day 0 Day 1 , 400μL per wound site ) . Wound margin injection define extend 0.5cm either end incision . Four dos avotermin ( Juvista ) administer subject : 5ng , 50ng , 200ng 500ng/100μL per linear cm ; one dose one wound site per anatomically match pair wound . The second wound site anatomically match pair wound dose placebo . Allocation treatment wound-site pair randomise double blind . Primary objective To determine optimal concentration dose regimen Juvista improvement resultant scar apply approximate wound margin male female subject follow surgical incision . Secondary objective To assess safety tolerance Juvista apply approximate wound margin male female subject follow surgical incision .</brief_summary>
	<brief_title>Improvement Scar Appearance Following Injection Avotermin ( Juvista ) Into Skin Incisions Made Healthy Men Women</brief_title>
	<detailed_description />
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Males female age 1885 year give write informed consent . Subjects body mass index within 1535 kg/m2 ( Quetelet 's index ) . Subjects history evidence keloid scar . Subjects tattoo previous scar within 3cm area incise . Subjects surgery area incise within one year first dosing day . Subjects history bleed disorder receive anticoagulant antiplatelet therapy . Subjects evidence past present clinically significant disease may affect endpoint trial . Subjects clinically significant skin disorder chronic currently active . Subjects clinically significant medical condition history would impair wound heal . Subjects history hypersensitivity drug dressing use trial . Subjects take , take , investigational product participate clinical trial three month prior first trial dose administration . Subjects take regular , continuous , oral corticosteroid therapy . Subjects undergoing investigation change management exist medical condition . Subjects history drug abuse , positive drug abuse test cocaine , amphetamine , methamphetamine , opiates benzodiazepine screen period . Subjects , opinion investigator , unlikely complete trial whatever reason . Subjects clinically significant neurological impairment disease . Subjects active infection . Subjects pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Cicatrix</keyword>
	<keyword>Scar</keyword>
	<keyword>TGFβ3</keyword>
	<keyword>Avotermin</keyword>
	<keyword>Juvista</keyword>
	<keyword>RN1001</keyword>
</DOC>